Trial · NCT03452228
Results by group170
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 170
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants | Actual Cohort 3: DB Placebo/SB Evinacumab IV 15mg/kg Q4W | 19.2 | Standard Error 99.1 | Percent Change | |
| Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants | Actual Cohort 3: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W | -37.2 | Standard Error 42.9 | Percent Change | |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Placebo Q4W (DBTP) | Percent change at Week 2 | 1.99 | Standard Deviation 45.687 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Evinacumab IV 15mg/kg Q4W (DBTP) | Percent change at Week 2 | -51.38 | Standard Deviation 33.160 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Placebo Q4W (DBTP) | Percent change at Week 4 | -3.52 | Standard Deviation 41.029 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Evinacumab IV 15mg/kg Q4W (DBTP) | Percent change at Week 4 | -43.70 | Standard Deviation 39.119 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Placebo Q4W (DBTP) | Percent change at Week 6 | 92.56 | Standard Deviation 262.368 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Evinacumab IV 15mg/kg Q4W (DBTP) | Percent change at Week 6 | -52.69 | Standard Deviation 40.214 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Placebo Q4W (DBTP) | Percent change at Week 8 | 4.83 | Standard Deviation 38.941 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Evinacumab IV 15mg/kg Q4W (DBTP) | Percent change at Week 8 | -32.86 | Standard Deviation 64.787 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Placebo Q4W (DBTP) | Percent change at Week 12 | 17.47 | Standard Deviation 47.610 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Evinacumab IV 15mg/kg Q4W (DBTP) | Percent change at Week 12 | -42.03 | Standard Deviation 61.086 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Evinacumab IV 15mg/kg Q4W (SBTP) | Percent change at Week 16 | -39.23 | Standard Deviation 46.026 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Evinacumab IV 15mg/kg Q4W (SBTP) | Percent change at Week 20 | -38.09 | Standard Deviation 49.070 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab Overall Group | Evinacumab IV 15mg/kg Q4W (SBTP) | Percent change at Week 24 | -35.86 | Standard Deviation 65.011 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab in Actual Cohorts 1, 2, and 3 | Actual Cohort 1: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W | Percent change at Week 2 | -28.3 | Inter-Quartile Range -40.3 to -6.5 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab in Actual Cohorts 1, 2, and 3 | Actual Cohort 2: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W | Percent change at Week 2 | -77.5 | Inter-Quartile Range -81.2 to -58.9 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab in Actual Cohorts 1, 2, and 3 | Actual Cohort 3: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W | Percent change at Week 2 | -74.4 | Inter-Quartile Range -84.2 to -37.1 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab in Actual Cohorts 1, 2, and 3 | Actual Cohort 1: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W | Percent change at Week 4 | -19.0 | Inter-Quartile Range -69.6 to -2.7 | Percent Change |
| Percent Change From Baseline in Fasting TG Level Following 2 to 24 Weeks of Repeated IV Doses of Evinacumab in Actual Cohorts 1, 2, and 3 | Actual Cohort 2: DB Evinacumab/SB Evinacumab IV 15mg/kg Q4W | Percent change at Week 4 | -48.0 | Inter-Quartile Range -76.2 to -29.2 | Percent Change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03452228/results